Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Single Arm Study of Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer: the CHIMERA Study.

NCT07407465 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT07407465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07407465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Single Arm Study of Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer: the CHIMERA Study.
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 2
Overall status
Recruiting
Start date
October 20, 2025
Completion date
October 20, 2027
Enrollment
42 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer adenocarcinoma, colon cancer metastatic, colorectal adenocarcinoma, colorectal cancer, rectal adenocarcinoma, rectal cancer, adenocarcinoma, rectal cancer, metastatic